当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2018年, 第18卷, 第3期, 第161-167页
标题:
直接抗丙型肝炎病毒药物的药物相互作用
DOI:
10.5428/pcar20180301
作者:
1. 姜波(第二军医大学长征医院药学部 上海 200003 lucid1227@163.com)
2. 陈万生(第二军医大学长征医院药学部 上海 200003 chenws126@126.com)
摘要:
摘要  临床上与丙型肝炎直接抗病毒药物(direct-acting antiviral agents,DAA)相关的药物相互作用(drug-drug interaction,DDI)普遍存在,DDI的机制包括抑制或诱导细胞色素酶CYP450活性、抑制或激活多种转运蛋白和改变血浆蛋白结合。对治疗的影响主要有两方面,其一是合并用药影响DAA的暴露量,导致疗效降低或药品不良反应(ADRs)增多;其二是DAA影响合并用药的浓度,导致相应症状甚至发生严重不良事件。本文概述了DAA与临床常用药物,如血脂调节药、免疫抑制剂、抗反转录酶病毒药、中草药等药物合用的3种情况:(1)合用后DAA或合用药物浓度增加几倍甚至十几倍,产生严重ADRs,禁止合用;(2)合用后可能产生明显ADRs,需要加强监测、调整给药剂量和给药间隔时间;(3)预测合用后不会产生明显ADRs。
欢迎阅读《药学服务与研究》!您是该文第 168 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 姜波,陈万生. 直接抗丙型肝炎病毒药物的药物相互作用[J]. 药学服务与研究. 2018; 18(3): 161-167.
英文著录格式 JIANG Bo,CHEN WanSheng. Drug-drug interactions associated with direct-acting antiviral agents for hepatitis C[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(3): 161-167.
参考文献:
1. Mohd Hanafiah K, Groeger J, Flaxman A D, et al. Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology,2013,57(4):1333-1342.
2. World Health Organization. Hepatitis C fact sheet[EB/OL].(2017-10)[2018-01-22]. http://www.who.int/mediacentre/factsheets/fs164/en/.
3. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志,2015,23(12):906-923.Society of Hepatology, Chinese Medical Association;Society of Infectious Diseases, Chinese Medical Association. The guideline for prevention and treatment of hepatitis C:a 2015 update[J]. Chin J Hepatol,2015,23(12):906-923. In Chinese with English abstract.
4. World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection[EB/OL]. Updated version April 2016. (2016-04)[2018-01-22]. http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/.
5. Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection[J]. Dig Liver Dis,2014,46(Suppl 5):S165-S173.
6. Vermehren J, Peiffer K H, Welsch C,et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection[J]. Aliment Pharmacol Ther,2016,44(8):856-865.
7. US Food and Drug Administration. FDA Drug Safety Communication:FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug[EB/OL]. (2015-03-24)[2018-01-22]. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM439492.pdf.
8. Syal G, Heldenbrand S D, Duarte-Rojo A. Seizures as a potential complication of treatment with simeprevir and sofosbuvir[J]. Am J Ther,2016,23(2):e570-e571.
9. Puglisi G M, Smith S M, Jankovich R D, et al. Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin:a case report[J]. J Clin Pharm Ther,2017,42(1):115-118.
10. Feeney E R, Chung R T. Antiviral treatment of hepatitis C[J]. BMJ,2014,349:g3308.
11. Pelosi L A, Voss S, LIU MengPing,et al. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir[J]. Antimicrob Agents Chemother,2012,56(10):5230-5239.
12. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs[J]. Expert Opin Drug Metab Toxicol,2015,11(3):333-341.
13. Dick T B, Lindberg L S, Ramirez D D, et al. A clinician’s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection[J]. Hepatology,2016,63(2):634-643.
14. Tannenbaum C, Sheehan N L. Understanding and preventing drug-drug and drug-gene interactions[J]. Expert Rev Clin Pharmacol,2014,7(4):533-544.
15. Shapiro L E, Shear N H. Drug interactions:proteins, pumps, and P-450s[J]. J Am Acad Dermatol,2002,47(4):467-484.
16. Scavone C, Sportiello L, Rafaniello C, et al. New era in treatment options of chronic hepatitis C:focus on safety of new direct-acting antivirals (DAAs)[J]. Expert Opin Drug Saf,2016,15(Suppl 2):85-100.
17. Menon R M, Badri P S, WANG TianLi, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir[J]. J Hepatol,2015,63(1):20-29.
18. Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C[J]. Br J Clin Pharmacol,2017,83(2):269-293.
19. Highlights of prescribing information. Sovaldi (sofosbuvir) tablets, for oral use[EB/OL]. (2017-11)[2018-01-22].http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.
20. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy:challenges and solutions[J]. J Hepatol,2013,58(4):792-800.
21. Eley T, Garimella T, LI WenYing, et al. Asunaprevir:a review of preclinical and clinical pharmacokinetics and drug-drug interactions[J]. Clin Pharmacokinet, 2015,54(12):1205-1222.
22. Christensen S, Ansolabehere X, Mouaddin N E, et al. Comorbidities, co-medication and potential drug to drug interactions in chronic hepatitis C patients (CHC):implications for adequate HCV treatment selection-data from a large transversal study in Germany and France[J]. Hepatology,2016,64(1 Suppl):977A-978A.
23. University of Liverpool. Interaction report[EB/OL]. (2018-01-23) [2018-03-01].https://www.hep-druginteractions.org/.
24. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C,2016[J]. J Hepatol,2017,66(1):153-194.
25. Anon.Sunvepra (asunaprevir) product information[EB/OL]. (2017-01-12)[2018-01-22]. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01812-1&d=2017090516114622483&d=20180208 16114622483.
26. Wyles D L, Ruane P J, Sulkowski M S, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1[J]. N Engl J Med,2015,373(8):714-725.
27. ZHA JiuHong, Badri P S, Ding BiFeng, et al. Drug interactions between hepatoprotective agents ursodeoxycholic acid or glycyrrhizin and ombitasvir/paritaprevir/ritonavir in healthy Japanese subjects[J]. Clin Ther,2015,37(11):2560-2571.
28. Terrault N A, Zeuzem S, Di Bisceglie A M, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response[J]. Gastroenterology,2016,151(6):1131-1140.e5
29. Back D J, Burger D M. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection:potential mechanisms and lessons to be learned[J]. Gastroenterology,2015,149(6):1315-1317.
30. Feld J J, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks[J]. J Hepatol,2016,64(2):301-307.